Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...
Figure][1] Michael Teitell, MD, PhD Dr. Michael Teitell is the director of the UCLA Health Jonsson Comprehensive Cancer ...
Radiopharmaceutical therapy (RPT) offers molecular-targeted treatment strategies and presents an ideal model for advancing ...
There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.
See an invited perspective on this article on page 1412. Tumor growth and spread are determined not only by cancer cells but also by the nonmalignant constituents of the malignant lesion, which are ...
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA ligand. Although the case ...
Journal of Nuclear Medicine January 2026, jnumed.125.270906; DOI: https://doi.org/10.2967/jnumed.125.270906 ...
Journal of Nuclear Medicine September 2025, jnumed.125.269539; DOI: https://doi.org/10.2967/jnumed.125.269539 ...
The LFER 150 PET/CT device (large–field-of-view extreme-resolution portable research imager) is a system for nonhuman primate (NHP) imaging. The objective of this study was to evaluate the performance ...
Complaints of a dry mouth (xerostomia) and sialoadenitis are frequent side effects of radioiodine treatment in differentiated thyroid cancer (DTC) patients. However, detailed prospective data on ...
TO THE EDITOR: Radiopharmaceuticals for PET imaging are regulated as drugs by the U.S. Food and Drug Administration (FDA) through several offices within the Center for Drug Evaluation and Research, ...
Journal of Nuclear Medicine December 2025, jnumed.125.270792; DOI: https://doi.org/10.2967/jnumed.125.270792 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback